Ionis has shared a letter with the Angelman syndrome community in response to last week’s announcement on the outcome of the ASPIRE GTX-102 Phase 3 clinical trial.
The letter shares information about the obudanersen (ION582) program and addresses some of the questions Ionis has received from the community. Ionis remains committed to continue evaluating the safety and efficacy of obudanersen (ION582) through three clinical trials: HALOS, REVEAL, and CHAMPION.